tldrdailynews.com logo

Compass's Psychedelic Drug Achieves Key Phase 3 Success in Depression Treatment

1 min read
Source: Yahoo Finance
Compass's Psychedelic Drug Achieves Key Phase 3 Success in Depression Treatment
Photo: Yahoo Finance
TL;DR

Compass Pathways' psilocybin drug for treatment-resistant depression met its primary goal by reducing symptoms, but fell short of investor expectations, leading to a significant drop in stock price. The trial showed a modest 3.6-point improvement, with sustained benefits observed six weeks after a single dose, highlighting potential in psychedelic therapy for mental health treatment.

Topics:businesshealth#clinical-trial#depression#health#mental-health#psilocybin#psychedelic
Share this article
  1. Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial  Yahoo Finance
  2. Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle  Psychedelic Alpha
  3. Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed  Fierce Biotech
  4. Compass psilocybin therapy shown to be effective in largest-ever study in depression  STAT
  5. Compass Plots Path to FDA With ‘Meaningful’ Phase III Data for Psilocybin Drug in Depression  BioSpace

Want the full story? Read the original reporting

Read on Yahoo Finance